| Literature DB >> 35749589 |
Livia Ulicna1, Samuel C Kimmey1,2, Christopher M Weber1, Grace M Allard1, Aihui Wang1, Nam Q Bui2, Sean C Bendall1, Gerald R Crabtree1,3, Gregory R Bean1, Capucine Van Rechem1.
Abstract
Subunits from the chromatin remodelers mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) are mutated, deleted, or amplified in more than 40% of cancers. Understanding their functions in normal cells and the consequences of cancerous alterations will provide insight into developing new targeted therapies. Here we examined whether mSWI/SNF mutations increase cellular sensitivity to specific drugs. Taking advantage of the DepMap studies, we demonstrate that cancer cells harboring mutations of specific mSWI/SNF subunits exhibit a genetic dependency on translation factors and are sensitive to translation pathway inhibitors. Furthermore, mSWI/SNF subunits were present in the cytoplasm and interacted with the translation initiation machinery, and short-term inhibition and depletion of specific subunits decreased global translation, implicating a direct role for these factors in translation. Depletion of specific mSWI/SNF subunits also increased sensitivity to mTOR-PI3K inhibitors. In patient-derived breast cancer samples, mSWI/SNF subunits expression in both the nucleus and the cytoplasm was substantially altered. In conclusion, an unexpected cytoplasmic role for mSWI/SNF complexes in translation suggests potential new therapeutic opportunities for patients afflicted by cancers demonstrating alterations in their subunits. SIGNIFICANCE: This work establishes direct functions for mSWI/SNF in translation and demonstrates that alterations in mSWI/SNF confer a therapeutic vulnerability to translation pathway inhibitors in cancer cells. ©2022 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35749589 PMCID: PMC9379364 DOI: 10.1158/0008-5472.CAN-21-1360
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312